Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs578776
rs578776
0.040 GeneticVariation BEFREE Gene polymorphisms of CHRNA3 (rs578776) and CHRNA4 (rs1044396 and rs2229959) were associated with the success of smoking cessation after the diagnosis of lung cancer, which should be considered in the management of smoking cessation after patients are diagnosed with lung cancer. 31402126

2020

dbSNP: rs34424986
rs34424986
0.020 GeneticVariation BEFREE Among all lung cancer-linked mutants that we tested, A46T Parkin failed to translocate onto mitochondria and could not recruit downstream mitophagic regulators, including optineurin (OPTN) and TFEB, whereas N254S and R275W Parkin displayed slower mitochondrial translocation than WT Parkin. 31285534

2020

dbSNP: rs1044396
rs1044396
0.010 GeneticVariation BEFREE Gene polymorphisms of CHRNA3 (rs578776) and CHRNA4 (rs1044396 and rs2229959) were associated with the success of smoking cessation after the diagnosis of lung cancer, which should be considered in the management of smoking cessation after patients are diagnosed with lung cancer. 31402126

2020

dbSNP: rs121912654
rs121912654
0.010 GeneticVariation BEFREE The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer. 31067569

2020

dbSNP: rs139600787
rs139600787
0.010 GeneticVariation BEFREE Among all lung cancer-linked mutants that we tested, A46T Parkin failed to translocate onto mitochondria and could not recruit downstream mitophagic regulators, including optineurin (OPTN) and TFEB, whereas N254S and R275W Parkin displayed slower mitochondrial translocation than WT Parkin. 31285534

2020

dbSNP: rs2229959
rs2229959
0.010 GeneticVariation BEFREE Gene polymorphisms of CHRNA3 (rs578776) and CHRNA4 (rs1044396 and rs2229959) were associated with the success of smoking cessation after the diagnosis of lung cancer, which should be considered in the management of smoking cessation after patients are diagnosed with lung cancer. 31402126

2020

dbSNP: rs2239611
rs2239611
0.010 GeneticVariation BEFREE Among individuals older than 50 years, we observed a protective effect of rs2284749 in the recessive model (P = 0.020) and log-additive model (P = 0.045), and rs2239611 associated with the decreased lung cancer risk under codominant (P = 0.037), dominant (P = 0.010), overdominant (P = 0.026) and log-additive (P = 0.015) models. 31794515

2020

dbSNP: rs2284749
rs2284749
0.010 GeneticVariation BEFREE Among individuals older than 50 years, we observed a protective effect of rs2284749 in the recessive model (P = 0.020) and log-additive model (P = 0.045), and rs2239611 associated with the decreased lung cancer risk under codominant (P = 0.037), dominant (P = 0.010), overdominant (P = 0.026) and log-additive (P = 0.015) models. 31794515

2020

dbSNP: rs483352697
rs483352697
0.010 GeneticVariation BEFREE The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer. 31067569

2020

dbSNP: rs756402191
rs756402191
0.010 GeneticVariation BEFREE The lung-enriched p53 mutants V157F and R158L/P regulate a gain of function transcriptome in lung cancer. 31067569

2020

dbSNP: rs776983107
rs776983107
0.010 GeneticVariation BEFREE Among all lung cancer-linked mutants that we tested, A46T Parkin failed to translocate onto mitochondria and could not recruit downstream mitophagic regulators, including optineurin (OPTN) and TFEB, whereas N254S and R275W Parkin displayed slower mitochondrial translocation than WT Parkin. 31285534

2020

dbSNP: rs778009684
rs778009684
0.010 GeneticVariation BEFREE Among all lung cancer-linked mutants that we tested, A46T Parkin failed to translocate onto mitochondria and could not recruit downstream mitophagic regulators, including optineurin (OPTN) and TFEB, whereas N254S and R275W Parkin displayed slower mitochondrial translocation than WT Parkin. 31285534

2020

dbSNP: rs1052133
rs1052133
0.100 GeneticVariation BEFREE Using the multifactor dimensionality reduction method, we found a model of gene-gene interactions associated with the risk of lung cancer: NBS1 (rs1805794)-XRCC1 (rs25487)-hOGG1 (rs1052133)-XPG (rs17655). 31584889

2019

dbSNP: rs1052133
rs1052133
0.100 GeneticVariation BEFREE To analyze the relationship of GSTT1, GSTM1, XRCC1 (rs25487), ERCC1 (rs11615, rs3212986), ERCC2 (rs13181), XRCC3 (rs861539), OGG1 (rs1052133), and Alpha-1-Antitrypsin mutations (AAT) with the risk of lung cancer in never-smokers, and ascertain if there is an effect modification between these polymorphisms and residential radon exposure. 31446980

2019

dbSNP: rs1057519847
rs1057519847
0.100 GeneticVariation BEFREE In this study, we applied ORNi-PCR to simultaneous detection of the de novo L858R and acquired T790M mutations in the <i>EGFR</i> gene in lung cancer cells. 31426517

2019

dbSNP: rs1057519847
rs1057519847
0.100 GeneticVariation BEFREE Electrochemical molecularly bioimprinted siloxane biosensor on the basis of core/shell silver nanoparticles/EGFR exon 21 L858R point mutant gene/siloxane film for ultra-sensing of Gemcitabine as a lung cancer chemotherapy medication. 31550632

2019

dbSNP: rs1057519847
rs1057519847
0.100 GeneticVariation BEFREE We detected the epidermal growth factor receptor L858R, MSH2 R929* and telomerase reverse transcriptase amplification in the lung cancer specimen; CDH1 c.1320+1G>T mutation in the gastric cancer (GC) specimen; and MLH1 c.1896+5G>A germline mutation in the lung and GC specimens by 450 cancer-related gene mutations detection using next-generation sequencing technology. 31207149

2019

dbSNP: rs1057519847
rs1057519847
0.100 GeneticVariation BEFREE EGFR exon 21 L858R as an acquired resistance mechanism to nivolumab in a lung cancer patient originally driver gene-negative. 30810279

2019

dbSNP: rs1057519847
rs1057519847
0.100 GeneticVariation BEFREE The identification of activating mutations in the epidermal growth factor receptor (EGFR) gene (deletions in exon 19 [Del19] and point mutation L858R in exon 21) has been the first important step toward molecularly guided precision therapy in lung cancer. 31564835

2019

dbSNP: rs1057519847
rs1057519847
0.100 GeneticVariation BEFREE Unusual synchronous double primary treatment-naïve lung adenocarcinoma harboring T790M and L858R mutations in early-stage lung cancer. 31426797

2019

dbSNP: rs1057519848
rs1057519848
0.100 GeneticVariation BEFREE The identification of activating mutations in the epidermal growth factor receptor (EGFR) gene (deletions in exon 19 [Del19] and point mutation L858R in exon 21) has been the first important step toward molecularly guided precision therapy in lung cancer. 31564835

2019

dbSNP: rs1057519848
rs1057519848
0.100 GeneticVariation BEFREE Electrochemical molecularly bioimprinted siloxane biosensor on the basis of core/shell silver nanoparticles/EGFR exon 21 L858R point mutant gene/siloxane film for ultra-sensing of Gemcitabine as a lung cancer chemotherapy medication. 31550632

2019

dbSNP: rs1057519848
rs1057519848
0.100 GeneticVariation BEFREE EGFR exon 21 L858R as an acquired resistance mechanism to nivolumab in a lung cancer patient originally driver gene-negative. 30810279

2019

dbSNP: rs1057519848
rs1057519848
0.100 GeneticVariation BEFREE We detected the epidermal growth factor receptor L858R, MSH2 R929* and telomerase reverse transcriptase amplification in the lung cancer specimen; CDH1 c.1320+1G>T mutation in the gastric cancer (GC) specimen; and MLH1 c.1896+5G>A germline mutation in the lung and GC specimens by 450 cancer-related gene mutations detection using next-generation sequencing technology. 31207149

2019

dbSNP: rs1057519848
rs1057519848
0.100 GeneticVariation BEFREE Unusual synchronous double primary treatment-naïve lung adenocarcinoma harboring T790M and L858R mutations in early-stage lung cancer. 31426797

2019